|By PR Newswire||
|March 17, 2014 03:00 AM EDT||
-- Company Increases Bioproduction Capabilities and Capacity
SAN CARLOS, California, March 17, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has acquired state-of-the-art laboratory operations in Budapest, Hungary from Codexis, Inc., a developer of biocatalysts for the pharmaceutical and complex chemistry industries.
The acquisition will expand Intrexon's strain and protein development capabilities, as well as strengthen fermentation process optimization and scale-up. Through the agreement, Intrexon's Industrial Products Division (IPD) will absorb the Budapest laboratory staff of experienced scientific professionals. Integration of the Budapest team and their expertise with Intrexon's suite of synthetic biology technologies and capabilities will allow Intrexon to better serve current collaborators and to attract new opportunities for active pharmaceutical ingredients (API) and industrial and consumer product collaborations.
Intrexon's IPD is positioned to develop biologically based solutions across sectors – Health, Food, Energy, Environment, and Consumer – including bioproduction of APIs, for example novel anti-infectives, as well as engineering microbial biocatalysts for chemical and fuel production.
"The expansion affords Intrexon greater flexibility in existing collaborations including Amneal, Johnson & Johnson, and Oragenics and positions the Company to meet demand from international collaborators," said Robert F. Walsh, President of Intrexon's Industrial Products Division. "We are pleased to integrate the Budapest team into Intrexon and look forward to their immediate contributions."
"The state-of-the-art industrial development facility and team we have acquired not only expands our current IPD operations, but its location in Budapest will enable us to continue growing our interests abroad and strengthen our ability to service the European and Asian markets," added Peter Seufer-Wasserthal, Ph.D., Vice President of Business Development for Europe and Asia.
About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment, and Consumer markets to create biologically-based products that improve the quality of life and the health of the planet. Through the company's proprietary UltraVector® platform, Intrexon provides its partners with industrial-scale design and development of complex biological systems. The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells. We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at www.dna.com.
Intrexon, UltraVector, RheoSwitch Therapeutic System, RTS, AttSite, mAbLogix, LEAP, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.
Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.
For more information contact:
Marie L. Rossi, Ph.D.
Manager, Technical Communications
Email: [email protected]
Aug. 27, 2016 02:45 PM EDT Reads: 3,437
Aug. 27, 2016 12:45 PM EDT Reads: 2,331
Aug. 27, 2016 12:30 PM EDT Reads: 3,608
Aug. 27, 2016 12:00 PM EDT Reads: 480
Aug. 27, 2016 12:00 PM EDT Reads: 621
Aug. 27, 2016 12:00 PM EDT Reads: 626
Aug. 27, 2016 11:00 AM EDT Reads: 3,964
Aug. 27, 2016 11:00 AM EDT Reads: 2,347
Aug. 27, 2016 10:30 AM EDT Reads: 1,958
Aug. 27, 2016 10:15 AM EDT Reads: 1,892
Aug. 27, 2016 08:45 AM EDT Reads: 759
Aug. 27, 2016 08:00 AM EDT Reads: 607
Aug. 27, 2016 07:45 AM EDT Reads: 792
Aug. 27, 2016 07:45 AM EDT Reads: 669
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Aug. 27, 2016 03:15 AM EDT Reads: 1,782